Target Information

Target General Information

Top

Target ID

T60345

Target Name

T-cell surface glycoprotein CD3 (CD3)

Synonyms

Cluster of differentiation 3

Click to Show/Hide

Gene Name

NO-GeName

Target Type

Successful target

[1]

Disease

[+] 5 Target-related Diseases

Diabetes mellitus [ICD-11: 5A10]

Diffuse large B-cell lymphoma [ICD-11: 2A81]

Follicular lymphoma [ICD-11: 2A80]

Mature B-cell lymphoma [ICD-11: 2A85]

Multiple myeloma [ICD-11: 2A83]

UniProt ID

NOUNIPROTAC

Drugs and Modes of Action

Top

Approved Drug(s)

[+] 7 Approved Drugs

Blinatumomab

Drug Info

Approved

Acute lymphoblastic leukaemia

[2], [3]

Elranatamab

Drug Info

Approved

Multiple myeloma

[4]

Epcoritamab

Drug Info

Approved

Diffuse large B-cell lymphoma

[5]

Glofitamab

Drug Info

Approved

Diffuse large B-cell lymphoma

[6]

Mosunetuzumab

Drug Info

Approved

Follicular lymphoma

[7]

Talquetamab

Drug Info

Approved

Multiple myeloma

[8]

Teplizumab

Drug Info

Approved

Type-1 diabetes

[9]

Clinical Trial Drug(s)

[+] 57 Clinical Trial Drugs

Nivatrotamab

Drug Info

Phase 2

Small-cell lung cancer

[10]

Odronextamab

Drug Info

Phase 2

B-cell non-hodgkin lymphoma

[11]

Otelixizumab

Drug Info

Phase 2

Type-1 diabetes

[12], [13]

Plamotamab

Drug Info

Phase 2

Diffuse large B-cell lymphoma

[14]

TAK-280

Drug Info

Phase 2

Aggressive cancer

[15]

Tarlatamab

Drug Info

Phase 2

Small-cell lung cancer

[16]

Acapatamab

Drug Info

Phase 1/2

Prostate cancer

[17]

GEN3013

Drug Info

Phase 1/2

Diffuse large B-cell lymphoma

[18]

ISB 1302

Drug Info

Phase 1/2

HER2-positive breast cancer

[19]

ISB 1342

Drug Info

Phase 1/2

Multiple myeloma

[20]

REGN4018

Drug Info

Phase 1/2

Ovarian cancer

[21]

REGN4336

Drug Info

Phase 1/2

Prostate cancer

[22]

REGN5458

Drug Info

Phase 1/2

Multiple myeloma

[23]

REGN5459

Drug Info

Phase 1/2

Multiple myeloma

[24]

SAR440234

Drug Info

Phase 1/2

Acute myeloid leukaemia

[25]

A-337

Drug Info

Phase 1

Non-small-cell lung cancer

[26]

ABBV-184

Drug Info

Phase 1

Non-small-cell lung cancer

[27]

AFM11

Drug Info

Phase 1

Non-hodgkin lymphoma

[28], [29]

AMG 160

Drug Info

Phase 1

Non-small-cell lung cancer

[30]

AMG 199

Drug Info

Phase 1

Gastric adenocarcinoma

[31]

AMG 330

Drug Info

Phase 1

Acute myeloid leukaemia

[29], [32]

AMG 340

Drug Info

Phase 1

Prostate cancer

[33]

AMG 424

Drug Info

Phase 1

Multiple myeloma

[34]

AMG 427

Drug Info

Phase 1

Acute myeloid leukaemia

[35]

AMG 596

Drug Info

Phase 1

Recurrent glioblastoma

[29], [36]

AMG 673

Drug Info

Phase 1

Acute myeloid leukaemia

[29]

AMG 701

Drug Info

Phase 1

Multiple myeloma

[29]

AMG 757

Drug Info

Phase 1

Small-cell lung cancer

[29]

AMG 910

Drug Info

Phase 1

Gastric adenocarcinoma

[37]

APVO436

Drug Info

Phase 1

Acute myeloid leukaemia

[38]

ASP2138

Drug Info

Phase 1

Stomach cancer

[39]

CCW702

Drug Info

Phase 1

Prostate cancer

[40]

CD20Bi aATC

Drug Info

Phase 1

Non-hodgkin lymphoma

[41]

CX-904

Drug Info

Phase 1

Colorectal cancer

[42]

GBR1302

Drug Info

Phase 1

Solid tumour/cancer

[43]

GEM333

Drug Info

Phase 1

Acute myeloid leukaemia

[44]

GEN1044

Drug Info

Phase 1

Solid tumour/cancer

[45]

IGM-2323

Drug Info

Phase 1

Non-hodgkin lymphoma

[46]

JNJ-63709178

Drug Info

Phase 1

Acute myeloid leukaemia

[29], [32]

JNJ-75348780

Drug Info

Phase 1

Non-hodgkin lymphoma

[47]

JNJ-78278343

Drug Info

Phase 1

Prostate cancer

[48]

M802

Drug Info

Phase 1

Solid tumour/cancer

[49]

MGD006

Drug Info

Phase 1

Acute myeloid lymphoma

[50], [51]

MGD014

Drug Info

Phase 1

Human immunodeficiency virus-1 infection

[52]

PF-07062119

Drug Info

Phase 1

Solid tumour/cancer

[53]

PF-07260437

Drug Info

Phase 1

Breast cancer

[54]

RG6007

Drug Info

Phase 1

Acute myeloid leukaemia

[55]

RG6156

Drug Info

Phase 1

Glioblastoma

[55]

RG6234

Drug Info

Phase 1

Multiple myeloma

[55]

RG6524

Drug Info

Phase 1

Aggressive cancer

[55]

Runimotamab

Drug Info

Phase 1

Breast cancer

[56]

SAR442257

Drug Info

Phase 1

Malignant neoplasm

[57]

SAR443216

Drug Info

Phase 1

Gastric cancer

[58]

Tepoditamab

Drug Info

Phase 1

Acute myelogenous leukaemia

[59]

TNB-383B

Drug Info

Phase 1

Multiple myeloma

[60]

TNB-486

Drug Info

Phase 1

B-cell lymphoma

[61]

WVT078

Drug Info

Phase 1

Multiple myeloma

[62]

Preclinical Drug(s)

[+] 1 Preclinical Drugs

IM1240

Drug Info

Preclinical

Aggressive cancer

[63]

Mode of Action

[+] 2 Modes of Action

Modulator

[+] 5 Modulator drugs

Blinatumomab

Drug Info

[1]

Glofitamab

Drug Info

[6]

Otelixizumab

Drug Info

[68]

CD20Bi aATC

Drug Info

[41]

MGD006

Drug Info

[50]

Inhibitor

[+] 30 Inhibitor drugs

Epcoritamab

Drug Info

[64]

Mosunetuzumab

Drug Info

[65]

Teplizumab

Drug Info

[66]

Nivatrotamab

Drug Info

[10]

ISB 1302

Drug Info

[73]

ISB 1342

Drug Info

[73]

REGN4018

Drug Info

[74]

REGN5458

Drug Info

[75]

REGN5459

Drug Info

[76]

A-337

Drug Info

[26]

AFM11

Drug Info

[78]

AMG 160

Drug Info

[79]

AMG 199

Drug Info

[79]

AMG 330

Drug Info

[80]

AMG 424

Drug Info

[79]

AMG 427

Drug Info

[79]

AMG 596

Drug Info

[79]

AMG 673

Drug Info

[79]

AMG 701

Drug Info

[79]

AMG 757

Drug Info

[79]

AMG 910

Drug Info

[79]

APVO436

Drug Info

[81]

GBR1302

Drug Info

[84]

GEM333

Drug Info

[85]

IGM-2323

Drug Info

[87]

JNJ-63709178

Drug Info

[88]

M802

Drug Info

[89]

MGD014

Drug Info

[90]

PF-07062119

Drug Info

[91]

SAR442257

Drug Info

[93]

References

Top

REF 1

2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.

REF 2

ClinicalTrials.gov (NCT02013167) Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

REF 3

ClinicalTrials.gov (NCT02393859) Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HR First Relapse B-precursor ALL

REF 4

FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761345

REF 5

FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761324.

REF 6

FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761309

REF 7

FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 761263.

REF 8

FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761342

REF 9

FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 761183.

REF 10

Clinical pipeline report, company report or official report of Y-mAbs Therapeutics.

REF 11

ClinicalTrials.gov (NCT05685173) A Phase 1 Study to Assess Safety and Tolerability of REGN5837, an Anti-CD22 x Anti-CD28 Costimulatory Bispecific Monoclonal Antibody, in Combination With Odronextamab, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients With Aggressive B-Cell Non-Hodgkin Lymphomas (ATHENA-1). U.S.National Institutes of Health.

REF 12

URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8458).

REF 13

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018350)

REF 14

ClinicalTrials.gov (NCT05328102) A Phase 2 Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of XmAb13676 (Plamotamab) Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma. U.S.National Institutes of Health.

REF 15

ClinicalTrials.gov (NCT05220098) A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-280 in Patients With Unresectable Locally Advanced or Metastatic Cancer. U.S.National Institutes of Health.

REF 16

ClinicalTrials.gov (NCT05060016) A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of Tarlatamab in Subjects With Relapsed/Refractory Small Cell Lung Cancer After Two or More Prior Lines of Treatment (DeLLphi-301). U.S.National Institutes of Health.

REF 17

ClinicalTrials.gov (NCT04631601) A Master Protocol Evaluating the Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC). U.S.National Institutes of Health.

REF 18

ClinicalTrials.gov (NCT03625037) GEN3013 Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. U.S. National Institutes of Health.

REF 19

ClinicalTrials.gov (NCT03983395) Study of ISB 1302 (CD3 Bispecific Ab) in HER2-positive Metastatic Breast Cancer. U.S. National Institutes of Health.

REF 20

ClinicalTrials.gov (NCT03309111) Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma. U.S. National Institutes of Health.

REF 21

ClinicalTrials.gov (NCT03564340) Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Patients With Recurrent Ovarian Cancer. U.S. National Institutes of Health.

REF 22

ClinicalTrials.gov (NCT05125016) Phase 1/2 Study of REGN4336 (a PSMAXCD3 Bispecific Antibody) Administered Alone or in Combination With Cemiplimab in Patients With Metastatic Castration-Resistant Prostate Cancer. U.S.National Institutes of Health.

REF 23

ClinicalTrials.gov (NCT03761108) First in Human (FIH) Study of REGN5458 in Patients With Relapsed or Refractory Multiple Myeloma. U.S. National Institutes of Health.

REF 24

ClinicalTrials.gov (NCT04083534) First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM). U.S. National Institutes of Health.

REF 25

ClinicalTrials.gov (NCT03594955) First in Human Testing of Dose-escalation of SAR440234 in Patients With Acute Myeloid Leukemia, Acute Lymphoid Leukemia and Myelodysplastic Syndrome. U.S. National Institutes of Health.

REF 26

Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019 Aug;18(8):585-608.

REF 27

ClinicalTrials.gov (NCT04272203) A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose (RP2D) of Intravenous ABBV-184 in Adult Participants With Previously Treated Cancers. U.S. National Institutes of Health.

REF 28

ClinicalTrials.gov (NCT02106091) Safety Study to Assess AFM11 in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHL or B-precursor ALL. U.S. National Institutes of Health.

REF 29

Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)

REF 30

ClinicalTrials.gov (NCT04822298) Study of AMG 160 in Subjects With Non-Small Cell Lung Cancer. U.S. National Institutes of Health.

REF 31

ClinicalTrials.gov (NCT04117958) Study of AMG 199 in Subjects With MUC17-Positive Gastric and Gastroesophageal Junction Cancer. U.S. National Institutes of Health.

REF 32

Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)

REF 33

ClinicalTrials.gov (NCT04740034) A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of AMG 340, a Bispecific Antibody Targeting PSMA in Subjects With Metastatic Castrate-Resistant Prostate Carcinoma. U.S.National Institutes of Health.

REF 34

ClinicalTrials.gov (NCT03445663) Study Evaluating AMG 424 in Subjects With Multiple Myeloma. U.S. National Institutes of Health.

REF 35

ClinicalTrials.gov (NCT03541369) Safety, Tolerability, PK, PD, and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (20170528). U.S. National Institutes of Health.

REF 36

Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)

REF 37

ClinicalTrials.gov (NCT04260191) Study of AMG 910 in Subjects With CLDN18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma. U.S. National Institutes of Health.

REF 38

ClinicalTrials.gov (NCT03647800) Study of APVO436 in Patients With AML or MDS. U.S. National Institutes of Health.

REF 39

ClinicalTrials.gov (NCT05365581) A Phase 1/1b Study of ASP2138 in Participants With Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma or Metastatic Pancreatic Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2 Expression. U.S.National Institutes of Health.

REF 40

ClinicalTrials.gov (NCT04077021) First-in-human Study of CCW702 in Patients With Metastatic Castration Resistant Prostate Cancer. U.S. National Institutes of Health.

REF 41

CD20-Targeted T Cells after Stem Cell Transplantation for High Risk and Refractory Non-Hodgkin's Lymphoma. Biol Blood Marrow Transplant. 2013 June; 19(6): 925-933.

REF 42

ClinicalTrials.gov (NCT05387265) A Phase 1/1b, Open-label, Dose-finding, First-in-human Study to Evaluate the Safety and Antitumor Activity of CX-904, an EGFR-targeted T-cell Engager in Advanced Solid Tumors (CTMX-904-101). U.S.National Institutes of Health.

REF 43

ClinicalTrials.gov (NCT02829372) Phase 1 Study of Single Agent GBR 1302 in Subjects With HER2 Positive Cancers (GBR 1302-101). U.S. National Institutes of Health.

REF 44

ClinicalTrials.gov (NCT03516760) Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia. U.S. National Institutes of Health.

REF 45

ClinicalTrials.gov (NCT04424641) A Study on the Safety of GEN1044 (DuoBody-CD3x5T4) in Subjects With Malignant Solid Tumors. U.S. National Institutes of Health.

REF 46

ClinicalTrials.gov (NCT04082936) A Safety and Pharmacokinetic Study of IGM-2323 in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma. U.S. National Institutes of Health.

REF 47

ClinicalTrials.gov (NCT04540796) A Phase 1, First-in-Human, Dose Escalation Study of the JNJ-75348780 Bispecific Antibody Targeting CD3 and CD22 in Participants With NHL and CLL. U.S.National Institutes of Health.

REF 48

ClinicalTrials.gov (NCT04898634) A Phase 1 Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer. U.S.National Institutes of Health.

REF 49

ClinicalTrials.gov (NCT04501770) A Study of M802 (HER2 and CD3) in HER2-Positive Advanced Solid Tumors. U.S. National Institutes of Health.

REF 50

A Phase I trial of MGD006 in patients with relapsed acute myeloid leukemia (AML). J Immunother Cancer. 2014; 2(Suppl 3): P87.

REF 51

ClinicalTrials.gov (NCT02152956) Safety Study of MGD006 in Relapsed/Refractory Acute Myeloid Leukemia (AML) or Intermediate-2/High Risk MDS

REF 52

ClinicalTrials.gov (NCT03570918) MGD014 in HIV-Infected Individuals on Suppressive Antiretroviral Therapy. U.S. National Institutes of Health.

REF 53

ClinicalTrials.gov (NCT04171141) Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.. U.S. National Institutes of Health.

REF 54

ClinicalTrials.gov (NCT05067972) A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMIC, AND ANTITUMOR ACTIVITY OF PF-07260437 IN ADVANCED OR METASTATIC SOLID TUMORS. U.S.National Institutes of Health.

REF 55

Clinical pipeline report, company report or official report of Roche

REF 56

ClinicalTrials.gov (NCT03448042) A Phase I Study of BTRC4017A in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers. U.S. National Institutes of Health.

REF 57

ClinicalTrials.gov (NCT04401020) First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL. U.S. National Institutes of Health.

REF 58

Clinical pipeline report, company report or official report of Sanofi

REF 59

ClinicalTrials.gov (NCT03038230) MCLA-117 in Acute Myelogenous Leukemia. U.S. National Institutes of Health.

REF 60

ClinicalTrials.gov (NCT03933735) A Study of TNB-383B in Subjects With Relapsed or Refractory Multiple Myeloma. U.S. National Institutes of Health.

REF 61

ClinicalTrials.gov (NCT04594642) A Study of TNB-486 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma. U.S. National Institutes of Health.

REF 62

ClinicalTrials.gov (NCT04123418) A Study of WVT078 in Patients With Multiple Myeloma (MM). U.S. National Institutes of Health.

REF 63

Clinical pipeline report, company report or official report of Purple

REF 64

Clinical pipeline report, company report or official report of Genmab.

REF 65

Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling. NPJ Syst Biol Appl. 2020 Aug 28;6(1):28.

REF 66

Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)

REF 67

Odronextamab, a human CD20*CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 2022 May;9(5):e327-e339.

REF 68

Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes.Diabetes Care.2014 Oct;37(10):2746-54.

REF 69

Plamotamab (XmAb(?)13676) for Ibrutinib- refractory CXCR4-mutated extramedullary Waldenstr?m macroglobulinemia. Leuk Lymphoma. 2022 Mar;63(3):738-742.

REF 70

Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study. J Clin Oncol. 2023 Jun 1;41(16):2893-2903.

REF 71

The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate Cancer. Clin Cancer Res. 2021 May 15;27(10):2928-2937.

REF 72

DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing. EBioMedicine. 2020 Feb;52:102625.

REF 73

Clinical pipeline report, company report or official report of Ichnos Sciences.

REF 74

A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancer. Sci Transl Med. 2019 Jun 19;11(497):eaau7534.

REF 75

A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells. Blood Adv. 2021 Mar 9;5(5):1291-1304.

REF 76

Clinical pipeline report, company report or official report of Regeneron Pharmaceuticals.

REF 77

Clinical pipeline report, company report or official report of AbbVie.

REF 78

A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells. MAbs. 2015;7(3):584-604.

REF 79

Clinical pipeline report, company report or official report of Amgen.

REF 80

Preclinical characterization of AMG 330, a CD3/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia. Mol Cancer Ther. 2014 Jun;13(6):1549-57.

REF 81

Clinical pipeline report, company report or official report of Aptevo.

REF 82

Clinical pipeline report, company report or official report of AbbVie.

REF 83

Clinical pipeline report, company report or official report of CytomX

REF 84

Clinical pipeline report, company report or official report of Glenmark Pharmaceuticals.

REF 85

Clinical pipeline report, company report or official report of Gemoab.

REF 86

Clinical pipeline report, company report or official report of AbbVie.

REF 87

Clinical pipeline report, company report or official report of IGM Biosciences.

REF 88

Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors. Curr Opin Hematol. 2018 Mar;25(2):136-145.

REF 89

A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells. J Exp Clin Cancer Res. 2019 Aug 14;38(1):355.

REF 90

Clinical pipeline report, company report or official report of MacroGenics.

REF 91

Discovery and optimization of a novel anti-GUCY2c x CD3 bispecific antibody for the treatment of solid tumors. MAbs. Jan-Dec 2021;13(1):1850395.

REF 92

Targeting HER2-positive breast cancer: advances and future directions. Nat Rev Drug Discov. 2023 Feb;22(2):101-126.

REF 93

Clinical pipeline report, company report or official report of Sanofi.

REF 94

MCLA-117, a CLEC12AxCD3 bispecific antibody targeting a leukaemic stem cell antigen, induces T cell-mediated AML blast lysis. Expert Opin Biol Ther. 2019 Jul;19(7):721-733.

REF 95

Clinical pipeline report, company report or official report of AbbVie.

REF 96

Clinical pipeline report, company report or official report of Teneobio.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.

Prof. Feng ZHU

Prof. Yuzong CHEN